The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore ‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common ...

In a first, the U.S. Food and Drug Administration has approved a treatment for cancer patients with specific genetic features in their tumors rather than a specific tumor type. The approval, based on ...

DPX-Survivac is an anti-cancer immunotherapy vaccine being developed by Immunovaccine for the treatment of certain types of cancer. How DPX-Survivac works DPX-Survivac is composed of survivin-based ...

Combining the investigational immunotherapy agent IMM-101 with chemotherapy significantly improved the survival of patients with advanced pancreatic cancer, compared to those who received chemotherapy ...

Monoclonal antibodies are lab-produced antibodies designed to bind to a specific target. In the context of immunotherapy, the target is typically specific to a type of cancer cell, or binds to an ...

Imfizi (durvalumab) has become the first approved immunotherapy in the United States for patients with advanced non-small cell lung cancer that has stabilized. The U.S. Food and Drug Admnistration ...

The U.S. Food and Drug Administration (FDA) has approved Imfinzi (durvalumab), in combination with standard chemotherapy, as an initial treatment of people with extensive-stage small cell lung cancer ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) to treat patients with metastatic small cell lung cancer (SCLC) who failed to respond to platinum-based chemotherapy and at least ...

France’s Institut Curie and the United States’ Freenome company will test whether an artificial intelligence technology focused on blood biomarkers can predict a person’s response to cancer treatment.

Viruses, like the flu virus, try to enter the cells in our body because they need a host to survive. Once inside, the virus begins to use the “machinery” of the cell to make copies of itself, ...

After failing to significantly extend survival in a confirmatory Phase 3 trial, Keytruda (pembrolizumab) will no longer be available in the U.S. for people with previously treated metastatic small ...

GBR 1342 is an antibody-based therapy being developed by Glenmark Pharmaceuticals to treat multiple myeloma and other cancers that overproduce CD38, a protein normally found on the surface of several ...